Emergence of a New Variant
A new variant of COVID-19, identified as BA.3.2 and informally named “Cicada,” is drawing global attention amid concerns of a possible resurgence. According to recent reports, the variant was highlighted in a study published on March 28, indicating its potential to spread rapidly and infect even those with prior immunity from vaccination or earlier infection.

Rapid Spread Across Countries
The new variant has reportedly been detected in at least 23 countries, including the United Kingdom. While the exact number of infections remains unclear, experts warn that the strain could soon become dominant in certain regions due to its high transmissibility.

Ability to Evade Immunity
Preliminary findings suggest that the “Cicada” variant may partially evade immunity developed through vaccines or previous infections. Although the virus itself remains similar, its behavior has changed, making it more capable of infecting a wider population. Common symptoms reported so far include fever, fatigue, body aches, and sore throat—similar to earlier COVID-19 strains.

Concerns for Children and Vulnerable Groups
Health experts are particularly concerned about the impact on children, especially school-going students. Stephen Griffin from the University of Leeds has warned that gaps in vaccination strategies could increase risks for younger populations. He emphasized the need to reconsider vaccination policies for children.

No Immediate Wave, But Risks Remain
Experts clarify that the current trajectory does not yet indicate a rapid surge like previous waves. However, continued spread increases the chances of further mutations, which could pose new challenges in the future.

Call for Renewed Vaccination Efforts
With vaccination rates declining globally, experts stress the importance of booster doses, especially for vulnerable groups. They highlight that vaccines remain effective in reducing severe illness, but only if coverage is maintained. Renewed vaccination efforts, particularly among children and high-risk individuals, are being strongly recommended.